Carcinogenesis Advance Access published online on November 28, 2007
Carcinogenesis, doi:10.1093/carcin/bgm269
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Overexpression of Cyclin B1 in Human Esophageal Squamous Cell Carcinoma (ESCC) Cells Induces Tumor Cell Invasive Growth and Metastasis
State key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
1 Correspondence should be addressed to Q.Z. (e-mail address: ZhanQimin{at}pumc.edu.cn, Telephone number: 0086-10-67762694, Fax number: 0086-10-67715058)
Cyclin B1, a key component in the control of cell cycle progression from G2 through to M phase, has been implicated in tumorigenesis and the development of malignancy. However, the underlying mechanism by which Cyclin B1 acts as an important oncogenic molecule remains largely unknown. Here we show ectopic expression of Cyclin B1 promotes cell proliferation, enhances cell motility and migration, results in increased ability of cells extravasating through the capillary endothelium. Interestingly, isogenic ESCC cells overexpressing Cyclin B1 reveals strong invasive growth and high potential of metastasis to lung in xenograft mice. Suppression of Cyclin B1 expression via siRNA approach in high-metastatic esophagus carcinoma cells specifically inhibits their ability to metastasize from the primary ESCC to lung. Notably, altered expression of epithelial markers and mesenchymal markers were observed in the cells overexpressing Cyclin B1, suggesting that Cyclin B1 contributes to metastasis probably by promoting an epithelial-mesenchymal transition (EMT). These results establish a mechanistic link between Cyclin B1, and ESCC metastasis, and provide novel insight into understanding of Cyclin B1 in the development of ESCC malignancy.
This work is supported by funding from the 973 National Key Fundamental Research Program of China (2002 CB513101) and the National Natural Science Foundation of China (30225018).
Received May 30, 2007; revised October 26, 2007; accepted November 20, 2007.